Clinical Trials

Enrolling Trials

1-10  of  144
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subject 2-17 Years of Age
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Child
This study sponsored by MedImmune aims to assess the effectiveness of the quadrivalent live-attenuated influenza vaccine (QLAIV) in children 2-17 years old when compared to the standard trivalent inactivated influenza vaccine (TIV) and to receiving no vaccine at all. The study will enroll children 2-17 years old with febrile acute respiratory illness who seek care in outpatient settings during influenza seasons starting in fall 2013 and ending after the 2017 influenza season. The vaccine was licensed by the FDA based on studies showing the vaccine generates adequate antibody levels.
Strey, Sandra K
(715) 389-4030
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors, No age restrictions
Mcmanus, Michael J
Biology
Child
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI  54449
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Mcmanus, Michael J
Biology
Child
The objectives of the study are to establish a mechanism to bank specimens to tumor cells and host germline DNA from patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse. To make these specimens available to qualified researchers to study the biology of ALL.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Chow, Brian
Infectious Disease - Other
Child
MEDI8897 is an experimental medications used to protect infants against Respiratory Syncytial Virus (RSV), which causes viral bronchiolitis and pneumonia. This is a major cause of hospitalization in children. It is expected that one dose of MEDI8897 can be given one to provide protection against RSV for the entire 5 months of RSV season. This study is being carried out to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a substance that looks like the study drug but it does not contain active ingredient.). The study will also measure medication levels of MEDI8897 at different dosages.
Johnson, Tara L
(715) 389-3509
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Hall, Matthew C
Infectious Disease - Other
Adult
This study is to evaluate the antiviral effect, pharmacokinetics, safety, and tolerability of GS-5806 in respiratory syncytial virus (RSV) positive adults who have been hospitalized with acute respiratory infectious symptoms. Participants will receive 1 dose of GS-5806 and followed for 28 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.
Freeman, Sandra K
(715) 387-9059
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients.
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Adult
The goal of this study is to learn more about how well people's bodies tolerate a dose of the RSV vaccine, to study the immune response to RSV vaccine in older adults, to find out how often people 60 years old and older get illnesses caused by respiratory viruses over a winter season, whether RSV vaccine has an effect that can be measured, and to find out how well flu shots and the RSV vaccine cause antibodies to be made when they are given together, as compared to when each is given alone. This information will help scientists to know more about the burden of illness caused by respiratory viruses and in developing a widely available vaccine to prevent RSV illness.
Strey, Sandra K
(715) 389-4030
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI  54449
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Mcmanus, Michael J
Brain, Spinal Cord - Other
Child
This phase II trial studies how well combination chemotherapy works in treating younger patients with newly diagnosed, non-metastatic desmoplastic medulloblastoma. Drugs used in chemotherapy, such as vincristine sulfate, cyclophosphamide, methotrexate, etoposide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Carpenter, Bonnie M
(715) 389-3639
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Onitilo, Adedayo A
Lung - Lung
Adult
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.
Bulgrin, Angela M
(715) 221-7261
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Bseiso, Ali W
Blood - CLL - Chronic Lymphocyctic
Adult
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab, can block cancer growth in difference ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet know whether rituximab with bendamustine hydrochloride is more effective than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia.
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI  54501
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Sacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI  54701
St. Clare's (Weston)
3400 Ministry Parkway
Weston, WI  54476
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
St. Mary's
2251 North Shore Drive
Rhinelander, WI  54501
St. Michaels Hospital
900 Illinois Ave
Stevens Point, WI  54481
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Wernberg, Jessica A
Breast - Breast
Adult
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known if radiation therapy alone is as effective as lymph node dissection and radiation therapy together.
Revels, Cheryl M
(715) 389-4177
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449